Information Provided By:
Fly News Breaks for October 12, 2015
TEAR
Oct 12, 2015 | 09:16 EDT
After First Coast Services, the Medicare Administrative Contractor with jurisdiction over Florida, published a final LCD determining tear osmolarity testing remains medically reasonable and necessary to aid in the diagnosis of moderate to severe dry eye disease, Roth Capital says the decision shows the clinical value of osmolarity testing. The firm also notes that the decision reduces the reimbursement uncertainty facing the company. It keeps a $4 price target and Buy rating on the shares.
News For TEAR From the Last 2 Days
There are no results for your query TEAR
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.